Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.54 |
| ▸ | NOS2 | P35228 | 4/20 | 0.54 |
| ▸ | NOS1 | P29475 | 2/20 | 0.54 |
| ▸ | GABRP | O00591 | 2/20 | 0.44 |
| ▸ | GABRD | O14764 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.44 |
| ▸ | GABRE | P78334 | 2/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1902299 | 0.98 | NOS3 (0.52) | NOS3NOS2NOS1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL17442658 | 0.98 | NOS3 (0.52) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL31486272 | 0.85 | NOS3 (0.43) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL4147975 | 0.82 | NOS3 (0.54) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL28963852 | 0.80 | NOS3 (0.52) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL584007 | 0.80 | CD274 (0.39) | NOS3NOS2NOS1GABRA1GABRB2 | |
| SCHEMBL4325085 | 0.79 | CCR1 (0.39) | NOS3NOS2AOC1AOC3KDM4E | |
| SCHEMBL24755263 | 0.78 | NOS2 (0.50) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL23491262 | 0.77 | NOS1 (0.48) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL3935249 | 0.77 | NOS3 (0.48) | NOS3NOS2NOS1GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934064-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-01-09 | — | — | EP | claimed |
| EP-0934064-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-08-11 | — | — | EP | claimed |
| WO-1998017274-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1998-04-30 | — | — | WO | claimed |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-12486278-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4626891-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | Omeros Corporation (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025076476-A2 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119350433-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-0934064-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0900207-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5869487-A | HIGH SELECTIVITY FOR THROMBIN; TREATING UNSTABLE ANGINA, MYOCARDIAL INFARCTION, ATRIAL FIBRILLATION, DEEP VEIN THROMBOSIS AND OTHER DISEASES | MERCK & CO., INC. (US) | 1999-02-09 | — | — | US | disclosed |
| US-5866573-A | Pyrazinone thrombin inhibitors | MERCK & CO., INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998031670-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1998-07-23 | — | — | WO | disclosed |
| WO-1998017274-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1998-04-30 | — | — | WO | disclosed |
| EP-0820453-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1998-01-28 | — | — | EP | disclosed |
| WO-1997040024-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-10-30 | — | — | WO | disclosed |
| WO-1996031504-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486278-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | NOS3 3501/4885NOS2 2487/4885NOS1 3702/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | NOS3 3590/4885NOS2 2617/4885NOS1 3800/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | NOS3 3706/4885NOS2 2639/4885NOS1 3865/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | NOS3 3590/4885NOS2 2617/4885NOS1 3800/4885 |
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | NOS3 2623/4885NOS2 1869/4885NOS1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.